87
Views
42
CrossRef citations to date
0
Altmetric
Research Article

Transforming Growth Factor-Beta 1, Activin and Follistatin in Patients with Hepatocellular Carcinoma and Patients with Alcoholic Cirrhosis

Pages 233-238 | Published online: 08 Jul 2009

  • Braun L, Mead JE, Panzica M, Mikurao R, Bell GI, Fausto N. Transforming growth factor ß mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc Natl Acad Sci USA 1988;85:1539-43.
  • Can BI, Hayashi I, Branum EL, Moses HL. Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type B transforming growth factor. Cancer Res 1986;46:2330-4.
  • Oberhammer F, Bursch W, Parafai l W, Breit P, Erber E, Stadler M, et al. Effect of transforming growth factor ß on cell death of cultured rate hepatocytes. Cancer Res 1991;51:2478-85.
  • Oberhammer F, Bursch W, Tiefenbacher R, Frosche G, Pavelka M, Purchio T, et al. Apoptosis is induced by transforming growth factor-ß1 within 5 hours in regressing liver without significant fragmentation of the DNA. Hepatology 1993;18: 1238-46.
  • Sporn MB, Roberts AB, Wakefleld LM, de Cromburgghe B. Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 1987;105:1039-45.
  • Castilla A, Prieto J, Fausto N. Transforming growth factors ß1 and á in chronic liver disease. Effects of interfereon alpha therapy. N Engl J Med 1991;324:933-40.
  • Shirari Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, et al. Plasma transforming growth factor-ß1 1 in patients with hepatocellular carcinoma. Comparsion with chronic liver diseases. Cancer 1994:73:2275-9.
  • Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, et al. Elevated urinary transforming growth factor-ß1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer 1997;76:244-50.
  • Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, et al. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991:51:4080-3.
  • Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-ß1 (TGF-ß1 ) and TGF-ß1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995; 21:760-6.
  • Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, Terrell TG. Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology 1993;18:347-56.
  • Hully JR, Chang L, Schwall RH, Widmer HR, Terrell TG, Gillet NA. Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology 1994;20:854-62.
  • Yasuka H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, et al. Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest 1993;92:1491 -6.
  • Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H. Activin-binding protein from ovary is follistatin. Science 1990; 247:836-8.
  • Michel U, Famworth UM, Findlay JK. Follistatin: more than follistatin-stimulatin g hormone suppressing proteins. MoI Cell Endocrinol 1993;91:1-11.
  • Zhang YQ, Kanzaki M, Shibata H, Kojima I. Regulation of the expression of follistatin in rat hepatocytes. Biochem Biophys Acta 1997:1354:204-10.
  • Gressner AM, Lahme B, Mannherz HG, Polzar B. TGf-ßmediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes. J Hepatol 1997;26:107992.
  • Miwa Y, Harriso n PM, Farzaneh F, Langley PG, Williams R, Hughes RD. Plasma levels and hepatic mRNA expression of transforming growth factor-ß1 1 in patients with fulminant hepatic failure. J Hepatol 1997;27:780-8.
  • Knight PG, Muttukrishna S, Groome NP. Development and application of a two-site enzyme immunoassay for the determination of 'total' activin-A concentrations in serum and follicular fluid. J Endocrinol 1996;148:267-79.
  • Evans LW, Muttukrishna S, Groome NP. Development, validation and application of an ultra-sensitive two-site enzyme immunoassay for human follistatin. J Endocrinol 1998; 156: 275-82.
  • Fausto N. Multifunctional roles for transforming growth factorß1. Lab Invest 1991;65:497-9.
  • Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, et al. Clinical evaluation of urinary transforming growth factor-ß1 and serum a -fetoprotein as tumour markers of hepatocellular carcinoma. Br J Cancer 1997;75:1460-6.
  • Shirai Y, Kawata S, Ito N, Tamura S, Takaishi K, Kiso S, et al. Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992:83:676-9.
  • Schuppan D, Atkinson J, Ruehl M, Riecken EO. Alcohol and liver fibrosis-palhobiochemistr y and treatment. Z Gastroenterol 1995:33:546-50.
  • Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver flbrogenesis. Hepatology 1990:11:599-605.
  • Lin HZ, Yang SQ, Zeldin G, Diehl AM. Chronic ethanol consumption induces the production of tumor necrosis factoralpha and related cytokines in liver and adipose tissue. Alcohol Clin Exp Res 1998;22 Suppl:231S-7S.
  • Yamaguchi M, Yu L, Hishikawa Y, Yamanoi A, Kubota H, Nagasue N. Growth kinetic study of human hepatocellular carcinoma using proliferating cell nuclear antigen and Lewis Y antigen: their correlation with transforming growth factor-alpha and beta 1. Oncology 1997;54:245-51.
  • Tanaka S, Wands JR. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor ß1 -induced apoptosis. Cancer Res 1996;56: 3391-4.
  • Sue SR, Chari RS, Kong FM, Mills JJ, Fine RL, Jirtle FL, Meyers WC. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann Surg 1995222:171-8.
  • Nishimura H, Harada T, Nawata J, Hayakawa M, Nishioka M, Takemoto T, et al. Relation of serum alkaline phosphatese to liver scintigram in patines with hepatocellular carcinoma. Hepatogastroenterolog y 1982;29:249-51.
  • Yao DF, Huang ZW, Chen SZ, Huang JF, Lu JX, Xiao MB, et al. Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specific bands of serum gamma-glutamyltransferase. Am J Clin Pathol 1998;! 10:743-9.
  • Sugiyama M, Ichida T, Sato T, Ishikawa T, Matsuda Y, Asakura H. Expression of activin A is increased in cirrhotic and fibrotic rat livers. Gastroenterology 1998;114:550-8.
  • Mashima H, Kanzaki M, Nobusawa R, Zhang YQ, Suzuki M, Mine T, et al. Derangements in the activin-follistati n system in hepatoma cells. Gastroenterology 1995;108:834-40.
  • Kehrl JH, Wakefleld LM, Roberts AB, Jakowlew S, AlvarezMon M, Derynck R, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986;163:1037-50.
  • Runyon BA. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology 1988:8:632-5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.